{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:59Z","timestamp":1787003399190,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Technology Research and Development Program in the Twelfth Five-year Plan Period of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Cordimax stent has proved non-inferior to the Cypher Select durable polymer sirolimus-eluting stent for the primary endpoint of angiographic in-stent late luminal loss and in-stent mean diameter stenosis at 9 months. The trial was designed to compare the efficacy and safety of the Cordimax stent with the Xience V stent in patients undergoing coronary revascularization. This randomized, multicenter trial enrolled 3697 patients treated with Cordimax stent (2460 patients) and Xience V stent (1237 patients). The primary efficacy endpoint was a target-lesion failure (TLF) at 1 year and the primary safety endpoint was a composite of death or myocardial infarction (MI) at 3 years. 3399 patients (91.9%) completed 3-year follow-up. At 1 year, the primary efficacy endpoint occurred in 86 (3.5%) patients in the Cordimax group versus 40 (3.2%) patients in the Xience V group (0.3% absolute risk difference, 95% CI \u22121.0\u20131.5%,\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>non-inferiority<\/jats:sub>\n                    \u2009&lt;\u20090.0001). At 3 years, the primary safety endpoint occurred in 39 (1.6%) patients in the Cordimax group versus 19 (1.5%) patients in the Xience V group (0.05% absolute risk difference, 95% CI \u22120.8\u20130.9%,\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>non-inferiority<\/jats:sub>\n                    \u2009&lt;\u20090.0001). The incidence of target lesion revascularization was low in Cordimax group compared with Xience V group (3.6% versus 5.1%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.03). There were no differences between Cordimax and Xience V in terms of Cardiac death (0.3% versus 0.4%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.70), myocardial infarction (1.2% versus 0.9%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.37), and the stent thrombosis (0.4% versus 0.6%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.61). In conclusion,\n                    <jats:bold>s<\/jats:bold>\n                    afety and efficacy outcomes of Cordimax stent were non-inferior to the Xience V stent 3 years after stent implantation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-54964-8","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:02:54Z","timestamp":1575612174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Haijun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-3641","authenticated-orcid":false,"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoutao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihai","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9640-8171","authenticated-orcid":false,"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"key":"54964_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"MC Morice","year":"2002","unstructured":"Morice, M. C. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346, 1773\u20131780, https:\/\/doi.org\/10.1056\/NEJMoa012843 (2002).","journal-title":"N Engl J Med"},{"key":"54964_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"GW Stone","year":"2004","unstructured":"Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350, 221\u2013231, https:\/\/doi.org\/10.1056\/NEJMoa032441 (2004).","journal-title":"N Engl J Med"},{"key":"54964_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","volume":"369","author":"J Daemen","year":"2007","unstructured":"Daemen, J. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667\u2013678, https:\/\/doi.org\/10.1016\/S0140-6736(07)60314-6 (2007).","journal-title":"Lancet"},{"key":"54964_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.058560","volume":"125","author":"L Raber","year":"2012","unstructured":"Raber, L. et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125, 1110\u20131121, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.058560 (2012).","journal-title":"Circulation"},{"key":"54964_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jcin.2008.08.004","volume":"1","author":"MC John","year":"2008","unstructured":"John, M. C. et al. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv 1, 535\u2013544, https:\/\/doi.org\/10.1016\/j.jcin.2008.08.004 (2008).","journal-title":"JACC Cardiovasc Interv"},{"key":"54964_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa, G. et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 57, 390\u2013398, https:\/\/doi.org\/10.1016\/j.jacc.2010.05.066 (2011).","journal-title":"J Am Coll Cardiol"},{"key":"54964_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(14)61794-3","volume":"385","author":"B Raungaard","year":"2015","unstructured":"Raungaard, B. et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet 385, 1527\u20131535, https:\/\/doi.org\/10.1016\/S0140-6736(14)61794-3 (2015).","journal-title":"Lancet"},{"key":"54964_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2741\/4491","volume":"22","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Drug release kinetics from a drug-eluting stent with asymmetrical coat. Front Biosci (Landmark Ed) 22, 407\u2013415 (2017).","journal-title":"Front Biosci (Landmark Ed)"},{"key":"54964_CR9","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1002\/ccd.25335","volume":"88","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Solely abluminal drug release from coronary stents could possibly improve reendothelialization. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 88, E59\u201366, https:\/\/doi.org\/10.1002\/ccd.25335 (2016).","journal-title":"Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions"},{"key":"54964_CR10","doi-asserted-by":"publisher","first-page":"e4820","DOI":"10.1097\/MD.0000000000004820","volume":"95","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine 95, e4820, https:\/\/doi.org\/10.1097\/MD.0000000000004820 (2016).","journal-title":"Medicine"},{"key":"54964_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40204-018-0097-y","volume":"7","author":"S Borhani","year":"2018","unstructured":"Borhani, S., Hassanajili, S., Ahmadi Tafti, S. H. & Rabbani, S. Cardiovascular stents: overview, evolution, and next generation. Progress in biomaterials 7, 175\u2013205, https:\/\/doi.org\/10.1007\/s40204-018-0097-y (2018).","journal-title":"Progress in biomaterials"},{"key":"54964_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/VHRM.S23388","volume":"8","author":"JC Townsend","year":"2012","unstructured":"Townsend, J. C., Rideout, P. & Steinberg, D. H. Everolimus-eluting stents in interventional cardiology. Vascular health and risk management 8, 393\u2013404, https:\/\/doi.org\/10.2147\/VHRM.S23388 (2012).","journal-title":"Vascular health and risk management"},{"key":"54964_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","volume":"6","author":"T Tada","year":"2013","unstructured":"Tada, T. et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC. Cardiovascular interventions 6, 1267\u20131274, https:\/\/doi.org\/10.1016\/j.jcin.2013.06.015 (2013).","journal-title":"JACC. Cardiovascular interventions"},{"key":"54964_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa067193","volume":"356","author":"GW Stone","year":"2007","unstructured":"Stone, G. W. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. The New England journal of medicine 356, 998\u20131008, https:\/\/doi.org\/10.1056\/NEJMoa067193 (2007).","journal-title":"The New England journal of medicine"},{"key":"54964_CR15","doi-asserted-by":"publisher","first-page":"f6625","DOI":"10.1136\/bmj.f6625","volume":"347","author":"S Bangalore","year":"2013","unstructured":"Bangalore, S. et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. Bmj 347, f6625, https:\/\/doi.org\/10.1136\/bmj.f6625 (2013).","journal-title":"Bmj"},{"key":"54964_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.amjcard.2011.12.019","volume":"109","author":"R Waksman","year":"2012","unstructured":"Waksman, R. et al. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. The American journal of cardiology 109, 1288\u20131294, https:\/\/doi.org\/10.1016\/j.amjcard.2011.12.019 (2012).","journal-title":"The American journal of cardiology"},{"key":"54964_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","volume":"59","author":"C von Birgelen","year":"2012","unstructured":"von Birgelen, C. et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. Journal of the American College of Cardiology 59, 1350\u20131361, https:\/\/doi.org\/10.1016\/j.jacc.2012.01.008 (2012).","journal-title":"Journal of the American College of Cardiology"},{"key":"54964_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.carrev.2016.09.010","volume":"18","author":"MA Gaglia Jr.","year":"2017","unstructured":"Gaglia, M. A. Jr. et al. Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry). Cardiovascular revascularization medicine: including molecular interventions 18, 16\u201321, https:\/\/doi.org\/10.1016\/j.carrev.2016.09.010 (2017).","journal-title":"Cardiovascular revascularization medicine: including molecular interventions"},{"key":"54964_CR19","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"S Bangalore","year":"2012","unstructured":"Bangalore, S. et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125, 2873\u20132891, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.097014 (2012).","journal-title":"Circulation"},{"key":"54964_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","volume":"33","author":"G Sarno","year":"2012","unstructured":"Sarno, G. et al. Lower risk of stent thrombosis and restenosis with unrestricted use of \u2018new-generation\u2019 drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 33, 606\u2013613, https:\/\/doi.org\/10.1093\/eurheartj\/ehr479 (2012).","journal-title":"Eur Heart J"},{"key":"54964_CR21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(11)60395-4","volume":"377","author":"S Silber","year":"2011","unstructured":"Silber, S., Windecker, S., Vranckx, P., Serruys, P. W. & investigators, R. A. C. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 377, 1241\u20131247, https:\/\/doi.org\/10.1016\/S0140-6736(11)60395-4 (2011).","journal-title":"Lancet"},{"key":"54964_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","volume":"58","author":"PC Smits","year":"2011","unstructured":"Smits, P. C. et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). Journal of the American College of Cardiology 58, 11\u201318, https:\/\/doi.org\/10.1016\/j.jacc.2011.02.023 (2011).","journal-title":"Journal of the American College of Cardiology"},{"key":"54964_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/heart.89.5.495","volume":"89","author":"CH Lee","year":"2003","unstructured":"Lee, C. H., Lemos, P. A. & Serruys, P. W. Acquired coronary artery fistula leading to acute myocardial infarction after endomyocardial biopsy. Heart 89, 495 (2003).","journal-title":"Heart"},{"key":"54964_CR24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.108.803528","volume":"119","author":"GW Stone","year":"2009","unstructured":"Stone, G. W. et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119, 680\u2013686, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.803528 (2009).","journal-title":"Circulation"},{"key":"54964_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jcin.2010.11.006","volume":"4","author":"E Grube","year":"2011","unstructured":"Grube, E. et al. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. JACC Cardiovasc Interv 4, 168\u2013175, https:\/\/doi.org\/10.1016\/j.jcin.2010.11.006 (2011).","journal-title":"JACC Cardiovasc Interv"},{"key":"54964_CR26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini, G. G. et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 33, 1214\u20131222, https:\/\/doi.org\/10.1093\/eurheartj\/ehs086 (2012).","journal-title":"Eur Heart J"},{"key":"54964_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","volume":"62","author":"M Natsuaki","year":"2013","unstructured":"Natsuaki, M. et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 62, 181\u2013190, https:\/\/doi.org\/10.1016\/j.jacc.2013.04.045 (2013).","journal-title":"J Am Coll Cardiol"},{"key":"54964_CR28","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","volume":"27","author":"AV Finn","year":"2007","unstructured":"Finn, A. V. et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27, 1500\u20131510, https:\/\/doi.org\/10.1161\/ATVBAHA.107.144220 (2007).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"54964_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu, K. et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123, 1400\u20131409, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.003210 (2011).","journal-title":"Circulation"},{"key":"54964_CR30","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1161\/CIRCULATIONAHA.109.849877","volume":"120","author":"S Silber","year":"2009","unstructured":"Silber, S. et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 120, 1498\u20131504, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.849877 (2009).","journal-title":"Circulation"},{"key":"54964_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1161\/CIRCULATIONAHA.111.063644","volume":"125","author":"LO Jensen","year":"2012","unstructured":"Jensen, L. O. et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 125, 1246\u20131255, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.063644 (2012).","journal-title":"Circulation"},{"key":"54964_CR32","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip, D. E. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115, 2344\u20132351, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313 (2007).","journal-title":"Circulation"},{"key":"54964_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ahj.2011.09.010","volume":"162","author":"J Gomez-Lara","year":"2011","unstructured":"Gomez-Lara, J. et al. Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. Am Heart J 162, 1069\u20131079 e1062, https:\/\/doi.org\/10.1016\/j.ahj.2011.09.010 (2011).","journal-title":"Am Heart J"},{"key":"54964_CR34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe, R. G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17, 873\u2013890 (1998).","journal-title":"Stat Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54964-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:05:01Z","timestamp":1671278701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54964-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54964"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54964-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Haijun Zhang, Shenguo Wang and Junbo Ge are together holding intellectual property rights on the technology, licensed to Rientech Inc., which manufacture stents based on the technology described in the paper. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"18549"}}